Aims: Low-dose radiation therapy (LDRT) can increase biological efficacy of chemotherapy. This Phase II trial evaluates LDRT plus FOLFIRI-bevacizumab (FOLFIRI-B) in metastatic colorectal cancer. Materials & methods: Primary objective: raising the clinical complete response rate from 5 to 25%. Secondary objectives: toxicity, progression-free survival. Patients underwent 12 FOLFIRI-B cycles plus two daily LDRT fractions (20 cGy/6 h interval) on each cycle. Statistical analysis was planned on 18 patients. Results: Results on 18 patients are reported. Specifically considering irradiated sites: 15/18 patients had a partial (11/18) or complete (4/18) response. Among 11 partial responders, three became a pathological CR after surgery. Grade 3-4 toxicity was recorded in two patients (11.1%). At median follow-up of 30 months (range: 8-50), 7/18 patients progressed in irradiated sites. Conclusion: Seven out of 18 patients (38.9%) had clinical or pathological CR in lesions treated with LDRT. Further studies on this newer treatment modality seem justified.

Morganti, A. G., Cellini, F., Mignogna, S., Padula, G. D., Caravatta, L., Deodato, F., Picardi, V., Macchia, G., Cilla, S., Buwenge, M., Lullo, L. D., Gambacorta, M. A., Balducci, M., Mattiucci, G. C., Autorino, R., Valentini, V., Low-dose radiotherapy and concurrent FOLFIRI-bevacizumab: A Phase II study, <<FUTURE ONCOLOGY>>, 2016; 12 (6): 779-787. [doi:10.2217/fon.15.350] [http://hdl.handle.net/10807/92456]

Low-dose radiotherapy and concurrent FOLFIRI-bevacizumab: A Phase II study

Morganti, Alessio Giuseppe;Cellini, Francesco;Mignogna, Samantha;Caravatta, Luciana;Deodato, Francesco;Picardi, Vincenzo;Cilla, Savino;Gambacorta, Maria Antonietta;Balducci, Mario;Mattiucci, Gian Carlo;Autorino, Rosa;Valentini, Vincenzo
2016

Abstract

Aims: Low-dose radiation therapy (LDRT) can increase biological efficacy of chemotherapy. This Phase II trial evaluates LDRT plus FOLFIRI-bevacizumab (FOLFIRI-B) in metastatic colorectal cancer. Materials & methods: Primary objective: raising the clinical complete response rate from 5 to 25%. Secondary objectives: toxicity, progression-free survival. Patients underwent 12 FOLFIRI-B cycles plus two daily LDRT fractions (20 cGy/6 h interval) on each cycle. Statistical analysis was planned on 18 patients. Results: Results on 18 patients are reported. Specifically considering irradiated sites: 15/18 patients had a partial (11/18) or complete (4/18) response. Among 11 partial responders, three became a pathological CR after surgery. Grade 3-4 toxicity was recorded in two patients (11.1%). At median follow-up of 30 months (range: 8-50), 7/18 patients progressed in irradiated sites. Conclusion: Seven out of 18 patients (38.9%) had clinical or pathological CR in lesions treated with LDRT. Further studies on this newer treatment modality seem justified.
eng
http://www.futuremedicine.com/loi/fon
Morganti, A. G., Cellini, F., Mignogna, S., Padula, G. D., Caravatta, L., Deodato, F., Picardi, V., Macchia, G., Cilla, S., Buwenge, M., Lullo, L. D., Gambacorta, M. A., Balducci, M., Mattiucci, G. C., Autorino, R., Valentini, V., Low-dose radiotherapy and concurrent FOLFIRI-bevacizumab: A Phase II study, <>, 2016; 12 (6): 779-787. [doi:10.2217/fon.15.350] [http://hdl.handle.net/10807/92456]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/92456
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact